Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof
21.7.2022 18:00:00 EEST | Business Wire | Press release
Innovaderm’s involvement in all phases of the clinical development of tapinarof culminated with a tremendous achievement: the recent approval of Dermavant Sciences’ VTAMA® (tapinarof) cream by the FDA for the treatment of plaque psoriasis in adults.
Discovered in Canada, tapinarof is approved in the United States for the management of psoriasis, a chronic skin condition that causes itchy, scaly patches on different parts of the body and has a significant detrimental effect on quality of life.
“This is a great milestone for patients – one that we have been working towards for years,” says Dr. Robert Bissonnette, Innovaderm’s founder and CEO. “Innovaderm is well-positioned to help companies such as Dermavant drive innovation forward by accompanying them in all stages of their clinical research from protocol writing to data analysis. We not only played an instrumental role through our participation in multicenter phase 2 and 3 studies, but we were also the first to demonstrate tapinarof’s efficacy in proof-of-concept studies in both psoriasis and atopic dermatitis.”
VTAMA® cream is a once-daily, topical medication for psoriasis. Currently, clinical trials are underway to study this medication among patients with atopic dermatitis.
“VTAMA® cream is a non-steroidal topical that is a new chemical entity and the first-in-class therapy to be approved in the topical psoriasis space in 25 years,” says Anna Tallman, PharmaD, Vice-President of Medical Affairs at Dermavant Sciences. “We appreciate the collaboration and partnership with Dr. Bissonnette and Innovaderm to help bring forward an effective new treatment option in the United States that has the potential to benefit adults with plaque psoriasis across the entire disease severity spectrum – from mild to severe.”
Dr. Bissonnette and Tallman recently contributed to an article on the phase 3 tapinarof studies, which was published in the New England Journal of Medicine. To learn more: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2103629
For information on Innovaderm’s early to late phase study capabilities, visit our website.
IMPORTANT SAFETY INFORMATION
Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist approved in the US for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
See full Prescribing Information and Patient Information.
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
Dermavant Sciences
Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The company’s medical dermatology pipeline includes both approved and late-stage development product candidates the company believes may address important immuno-dermatological conditions, including plaque psoriasis and atopic dermatitis. For more information, please visit www.dermavant.com, and follow us on Twitter (@dermavant) and LinkedIn (Dermavant Sciences).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005175/en/
Contact information
For more information:
Kathy Giangaspero
Communications Specialist
Innovaderm Research Inc.
kgiangaspero@innovaderm.com
Anna Tallman
Vice-President, Medical Affairs
Dermavant Sciences
anna.tallman@dermavant.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Elisa Expands PON Deployment with Vecima’s All-PON™ Shelf, Delivering 10G Fiber Services in Estonia6.5.2026 14:30:00 EEST | Press release
Vecima Networks Inc. (TSX: VCM) announced today that leading telecommunications operator Elisa has deployed Vecima’s Entra EXS1610 All-PON™ Shelf for 10G Fiber-to-the-Home (FTTH) services for its subscribers in Estonia. In Estonia’s competitive broadband market, Elisa brings highly innovative solutions to its subscribers. Vecima’s EXS1610 supports multiple deployment use cases, including greenfield, targeted brownfields, rural edge-outs, hybrid fiber-coax (HFC) overbuilds, footprint extensions, and hub collapses. Its compact shelf footprint can help reduce operating costs and allow operators to deploy anywhere – for maximum flexibility, including data centers, remote cabinets, the headend, and multi-dwelling units. The Entra EXS1610 All-PON Shelf features: 16 x PON ports: 10G-EPON, XGS-PON, and Combo XGS-PON & GPON Temperature-hardened for outside plant deployments Multi-vendor optical network terminal (ONT) interoperability Uplink optics: 2 x 100/40G & 2 x 25/10G with broad third-part
Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany6.5.2026 14:01:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-term, sustainable access agreement to a gene therapy has been established for people living with sickle cell disease and transfusion-dependent beta thalassemia,” said Ludovic Fenaux, Senior Vice President, Vertex International. “This agreement represents significant progress for people living with these two devastating and life-shortening diseases. We are pleased to collaborate across the health care system to ensure the value of CASGEVY is recognized and sustainable patient access is secured.” With this agreement, German
NIQ Launches AI-Powered Platform to Help Brands Test Pricing Decisions Before They Go to Market6.5.2026 14:00:00 EEST | Press release
As manufacturers face mounting pressure to protect margins, justify trade spend, and respond faster to shifting consumer demand, NIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the commercial launch of Price & Promo Optimizer, a next‑generation, AI‑enabled Revenue Growth Management (RGM) platform built to fundamentally change how pricing and promotion decisions are made. Today, many pricing and promotion decisions are still made across disconnected tools, manual workflows, and siloed teams—slowing execution, increasing risk, and limiting the ability to validate strategies before they reach the market. Price & Promo Optimizer replaces this fragmented approach with a united platform that brings pricing, promotion, and trade strategy into a single workflow. Powered by NIQ’s trusted store‑level measurement data and advanced analytical models, Price & Promo Optimizer enables category managers, RGM leaders, marketing, and commercial teams to simulate scenarios, qua
Suzano Connects an Area the Size of Over 200,000 Soccer Fields Through Ecological Corridors in Just Four Years6.5.2026 14:00:00 EEST | Press release
Suzano, the world's largest pulp supplier, has connected 214,368 hectares of native forest in the Atlantic Forest, Cerrado, and Amazon biomes in Brazil by establishing ecological corridors, restoring an area larger than 200,000 soccer fields within four years. In 2025 alone, 55,366 hectares of native forest were connected, advancing Suzano’s public goal of connecting 500,000 hectares by 2030, as outlined in the Company’s recently published Sustainability Report. The implementation of ecological corridors is guided by decades of research and monitoring by Suzano and its partners. The aim is to connect larger fragments of land that host greater biodiversity, as well as those already monitored by experts, with sites where wildlife is limited or threatened. These corridors are designed to follow the shortest possible route, increasing the likelihood of them being used by wildlife to better support their movement. "This connection allows animals to access different areas, increasing wildlif
From Checkout to Check-In: Klarna and Minor Hotels Bring Flexible Payments to Europe6.5.2026 13:56:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, and Minor Hotels, one of the world's leading hospitality groups, today announced a new partnership bringing Klarna's payments to travellers booking across Europe, just in time for the summer holiday season. With over 640 hotels, resorts and branded residences in operation and committed development across 63 countries, the group crafts innovative and insightful experiences through its hotel brands including Anantara, Elewana Collection, The Wolseley Hotels, Tivoli, Minor Reserve Collection, NH Collection, nhow, Avani, Colbert Collection, NH, Oaks, and iStay, as well as a diverse portfolio of restaurants and bars, travel experiences, and spa and wellness brands. Guests booking through Minor Hotel can now choose how they pay at checkout, whether that's paying immediately or splitting the cost into three interest-free installments, giving travellers greater financial flexibility when planning their dream trips. The partnership
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom